Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (28138)	1/29/2006 2:47:46 PM
From: Skywatcher	Respond to of 48461

dispatch.com GRAB A RAT!!!!!!!

To: Bucky Katt who wrote (28138)	1/29/2006 10:42:15 PM
From: blind-geezer	Read Replies (2) \| Respond to of 48461

dude, is there some post on this thread that details how this list is constructed ???

To: Bucky Katt who wrote (28138)	1/30/2006 11:18:32 AM
From: Joe Smith	Read Replies (1) \| Respond to of 48461

Anyone here understand why UAL has lost 94% of its value since it the beginning of the year. It seems that they have good news of exiting bankruptcy and new shares in February. What happens to old shares in February. If they become worthless, then why were they worth over $1 not too long ago. Wasn't it obvious that they would become worthless? Will the same thing happen to DAL eventually? I am confused by all of this.

To: Bucky Katt who wrote (28138)	1/31/2006 8:12:14 AM
From: Findit	Read Replies (2) \| Respond to of 48461

DOR up a bunch in pm on news from last night. 6:53 PM EST January 30, 2006 MIAMI (Dow Jones)--DOR Biopharma Inc. (DOR) said its Phase 1 study of RiVax as a vaccine against ricin toxin indicated that the vaccine is well-tolerated and induces antibodies in humans that neutralize ricin. Ricin toxin is a toxic protein extracted from castor beans that, in small amounts, can be deadly to humans and animals. In a press release Monday, the drug company said RiVax induced antibodies in all five participants injected with the highest dose level, four who received the intermediate dose and one with the lowest dosage. The study, conducted at the University of Texas Southwestern Medical Center, enrolled 15 volunteers in groups of five, who were vaccinated with three successive monthly injections of the same RiVax dose level. Side effects in the study were mild and included transient headaches and sore arms, DOR said in the release. Antibodies remained present in several participants' blood for 127 days following the last vaccination. Their presence was tested by transferring serum globulins, a protein fraction of serum composed chiefly of antibodies, from vaccinated participants along with active ricin toxin to sensitive mice. The mice survived, indicating the antibodies were active. DOR is conducting studies in mice to determine if the vaccine protects them against ricin administered by aerosols or orally instead of by injection. The company said the next steps for RiVax development will include evaluation to correlate protection against ricin exposure in animals to immune responses in vaccinated humans. -Dorna Naseri; Dow Jones Newswires; 201-938-5400; AskNewswires@dowjones.com (END) Dow Jones Newswires 01-30-06 1853ET Copyright (c) 2006 Dow Jones & Company, Inc.